ArticleScientific reports2025
Pharmacological risks of khat-oral antidiabetic drug interactions among patients at Gondar university referral hospital.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKhat (Catha edulis), a psychoactive plant commonly chewed in Ethiopia, is known to influence drug metabolism through its active compound, cathinone. Among patients with T2DM, concurrent khat chewing and OAD use may result in pharmacokinetic and pharmacodynamic interactions, particularly in polypharmacy contexts. Despite these concerns, the clinical relevance of khat-OAD interactions remains poorly understood in high-prevalence, low-resource settings.
methodsThis study assessed the prevalence, predictors, and perceptions of potential khat-OAD interactions among T2DM patients. A convergent parallel mixed-methods design was employed from July 1 to December 30, 2024, at Gondar University Hospital, Ethiopia. A total of 422 adult T2DM patients on OAD therapy who reported khat use were systematically sampled. Quantitative data on demographics, clinical profiles, medication use, and khat chewing behaviors were collected through structured interviews and verified via medical records. Potential interactions were identified using drug interaction databases, and logistic regression was used to determine independent predictors. Additionally, in-depth interviews with 20 patients and healthcare providers explored awareness, perceptions, and clinical experiences related to khat use and diabetes care.
resultsAmong the 422 participants, 63.3% (n = 267) had at least one potential khat-OAD interaction, and 23.2% (n = 98) experienced a major interaction. The most frequently implicated drugs were glibenclamide and sitagliptin. Significant predictors of interaction included female sex (AOR = 1.38; 95% CI: 1.00-1.89), polypharmacy with ≥ 7 medications (AOR = 2.43; 95% CI: 1.61-3.67), daily khat use (AOR = 2.20; 95% CI: 1.52-3.18), and khat use for ≥ 13 years (AOR = 1.09; 95% CI: 1.04-1.15). Qualitative findings highlighted the widespread cultural normalization of khat chewing, low patient awareness of potential interactions, and gaps in provider counseling.
conclusionsHarmful khat-OAD interactions are common among T2DM patients in Northwest Ethiopia, primarily driven by behavioral and treatment-related factors, highlighting the need for culturally sensitive pharmacovigilance and patient education. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.